2022
Seminars in Cancer Biology
review
Sex dimorphism in the tumor microenvironment : From bench to bedside and back
Fei He, Andrea Rodgers Furones, Nils Landegren, Jonas Fuxe, Dhifaf Sarhan
Abstract
Cancer represents a significant cause of death and suffering in both the developed and developing countries. Key underlying issues in the mortality of cancer are delayed diagnosis and resistance to treatments. However, improvements in biomarkers represent one important step that can be taken for alleviating the suffering caused by malignancy. Precision-based medicine is promising for revolutionizing diagnostic and treatment strategies for cancer patients worldwide. Contemporary methods, including various omics and systems biology approaches, as well as advanced digital imaging and artificial intelligence, allow more accurate assessment of tumor characteristics at the patient level. As a result, treatment strategies can be specifically tailored and adapted for individual and/or groups of patients that carry certain tumor characteristics. This includes immunotherapy, which is based on characterization of the immunosuppressive tumor microenvironment (TME) and, more specifically, the presence and activity of immune cell subsets. Unfortunately, while it is increasingly clear that gender strongly affects immune regulation and response, there is a knowledge gap concerning differences in sex-specific immune responses and how these contribute to the immunosuppressive TME and the response to immunotherapy. In fact, sex dimorphism is poorly understood in cancer progression and is typically ignored in current clinical practice. In this review, we aim to survey the available literature and highlight the existing knowledge gap in order to encourage further studies that would contribute to understanding both gender-biased immunosuppression in the TME and the driver of tumor progression towards invasive and metastatic disease. The review highlights the need to include sex optimized/genderized medicine as a new concept in future medicine cancer diagnostics and treatments.
DOI
DiVA
2022
thesis
Utvecklingen av antika berättelser : Skildringar av <i>Odysséens </i>och <i>Aeneidens </i>underjord.
Emma Bergström
Abstract
Science has studied ancient litterateur and poetry for a long time. This paper has chosen to turn its eyes towards Virgil’s Aeneid as its focus. One of the central points and the theory of the paper is to explore the ways in which the time Virgil lived have affected how he wrote the Aeneid as well as the reason for writing. Another theory that has been raised is if Virgil's work was affected by the current political changes during his lifetime, especially since he had a friendly relationship with the emperor Augustus, and if thus the Aeneid was written as a possible use of propaganda. To find an answer to the theories I have looked and presented the similarities and differences in the why the heroes travelled to the underworld, the journey itself and interactions of the two heroes with others during their time going towards the underworld as well as during their time there. The main material were the two authors’ narratives of the underworld, specifically the sixth book of the Aeneid and the eleventh book of the Odyssey, set in relation to modern research on these topics. The texts have been approached by close reading to further understand Virgil’s text and choices, and how the political views have been incorporated into his work. By reading the works and comparing the two narratives following the three analytical points, consistently and multiple times, as well as modern research, it could be concluded that Virgil's rendering of the narrative was a product of his own time, especially visible in the significant number of references to the Roman Empire and its leaders.
Full text
DiVA
2022
Journal of Clinical Immunology
article-journal
X-Linked TLR7 Deficiency Underlies Critical COVID-19 Pneumonia in a Male Patient with Ataxia-Telangiectasia
Hassan Abolhassani, Ahmad Vosughimotlagh, Takaki Asano, Nils Landegren, Bertrand Boisson, Samaneh Delavari, Paul Bastard, Maribel Aranda-Guillen, Yating Wang, Fanglei Zuo, Fabian Sardh, Harold Marcotte, Likun Du, Shen-Ying Zhang, Qian Zhang, Nima Rezaei, Olle Kampe, Jean-Laurent Casanova, Lennart Hammarstrom, Qiang Pan-Hammarstrom
Abstract
Background Coronavirus disease 2019 (COVID-19) exhibits a wide spectrum of clinical manifestations, ranging from asymptomatic to critical conditions. Understanding the mechanism underlying life-threatening COVID-19 is instrumental for disease prevention and treatment in individuals with a high risk.Objectives We aimed to identify the genetic cause for critical COVID-19 pneumonia in a patient with a preexisting inborn error of immunity (IEI).Methods Serum levels of specific antibodies against the virus and autoantibodies against type I interferons (IFNs) were measured. Whole exome sequencing was performed, and the impacts of candidate gene variants were investigated. We also evaluated 247 ataxia-telangiectasia (A-T) patients in the Iranian IEI registry.Results We report a 7-year-old Iranian boy with a preexisting hyper IgM syndrome who developed critical COVID-19 pneumonia. IgM only specific COVID-19 immune response was detected but no autoantibodies against type I IFN were observed. A homozygous deleterious mutation in the ATM gene was identified, which together with his antibody deficiency, radiosensitivity, and neurological signs, established a diagnosis of A-T. Among the 247 A-T patients evaluated, 36 had SARS-CoV-2 infection, but all had mild symptoms or were asymptomatic except the index patient. A hemizygous deleterious mutation in the TLR7 gene was subsequently identified in the patient.Conclusions We report a unique IEI patient with combined ATM and TLR7 deficiencies. The two genetic defects underlie A-T and critical COVID-19 in this patient, respectively.
DOI
DiVA
2021
Nature Communications
article-journal
GWAS for autoimmune Addison's disease identifies multiple risk loci and highlights AIRE in disease susceptibility
Daniel Eriksson, Ellen Christine Röyrvik, Maribel Aranda-Guillen, Amund Holte Berger, Nils Landegren, Haydee Artaza, Åsa Hallgren, Marianne Aardal Grytaas, Sara Ström, Eirik Bratland, Ileana Ruxandra Botusan, Bergithe Eikeland Oftedal, Lars Breivik, Marc Vaudel, Öyvind Helgeland, Alberto Falorni, Anders Palmström Jörgensen, Anna-Lena Hulting, Johan Svartberg, Olov Ekwall, Kristian Johan Fougner, Jeanette Wahlberg, Björn Gunnar Nedrebö, Per Dahlqvist, Per Morten Knappskog, Anette Susanne Böe Wolff, Sophie Bensing, Stefan Johansson, Olle Kämpe, Eystein Sverre Husebye
Abstract
Autoimmune Addison's disease (AAD) is characterized by the autoimmune destruction of the adrenal cortex. Low prevalence and complex inheritance have long hindered successful genetic studies. We here report the first genome-wide association study on AAD, which identifies nine independent risk loci (P<5x10(-8)). In addition to loci implicated in lymphocyte function and development shared with other autoimmune diseases such as HLA, BACH2, PTPN22 and CTLA4, we associate two protein-coding alterations in Autoimmune Regulator (AIRE) with AAD. The strongest, p.R471C (rs74203920, OR=3.4 (2.7-4.3), P=9.0x10(-25)) introduces an additional cysteine residue in the zinc-finger motif of the second PHD domain of the AIRE protein. This unbiased elucidation of the genetic contribution to development of AAD points to the importance of central immunological tolerance, and explains 35-41% of heritability (h(2)). Autoimmune Addison's disease is a rare complex disease, which has not yet been characterized by non-biased genetic studies. Here, the authors perform the first GWAS for the disease, identifying nine loci including two coding variants in the gene Autoimmune Regulator (AIRE).
DOI
DiVA
2021
Journal of Allergy and Clinical Immunology
article-journal
Severe COVID-19 in an APS1 patient with interferon autoantibodies treated with plasmapheresis
Andri Lemarquis, Tessa Campbell, Maribel Aranda-Guillén, Viktoria Hennings, Petter Brodin, Olle Kämpe, Kaj Blennow, Henrik Zetterberg, Christine Wennerås, Kristina Eriksson, Nils Landegren, Yenan Bryceson, Stefan Berg, Olov Ekwall
DOI
DiVA
2021
Journal of Neuroscience Research
article-journal
Visualization of early oligomeric α‐synuclein pathology and its impact on the dopaminergic system in the (Thy‐1)‐h[A30P]α‐syn transgenic mouse model
Anish Behere, Per-Ove Thörnqvist, Svante Winberg, Martin Ingelsson, Joakim Bergström, Sara Ekmark-Lewén
Abstract
Aggregation of alpha-synuclein (alpha-syn) into Lewy bodies and Lewy neurites is a pathological hallmark in the Parkinson ' s disease (PD) brain. The formation of alpha-syn oligomers is believed to be an early pathogenic event and the A30P mutation in the gene encoding alpha-syn, causing familial PD, has been shown to cause an accelerated oligomerization. Due to the problem of preserving antigen conformation on tissue surfaces, alpha-syn oligomers are difficult to detect ex vivo using conventional immunohistochemistry with oligomer-selective antibodies. Herein, we have instead employed the previously reported alpha-syn oligomer proximity ligation assay (ASO-PLA), along with a wide variety of biochemical assays, to discern the pathological progression of alpha-syn oligomers and their impact on the dopaminergic system in male and female (Thy-1)-h[A30P]alpha-syn transgenic (A30P-tg) mice. Our results reveal a previously undetected abundance of alpha-syn oligomers in midbrain of young mice, whereas phosphorylated (pS129) and proteinase k-resistant alpha-syn species were observed to a larger extent in aged mice. Although we did not detect loss of dopaminergic neurons in A30P-tg mice, a dysregulation in the monoaminergic system was recorded in older mice. Taken together, ASO-PLA should be a useful method for the detection of early changes in alpha-syn aggregation on brain tissue, from experimental mouse models in addition to post mortem PD cases.
DOI
DiVA
2020
thesis
"Kan jag också vara med?" : En kvalitativ studie om förskollärare och barnskötares arbete för en inkluderande verksamhet med barn i behov av särskilt stöd
Emma Bergström, Isa Henriksson
Abstract
I förskolan är det förskollärarnas och barnskötarnas uppgift att skapa en inkluderande verksamhet för samtliga barn i barngruppen samt att se till att alla barn i förskolan får sina behov tillgodosedda. Har förskollärare och barnskötare tillräcklig kompetens kring barn i behov av särskilt stöd och inkludering? Syftet med denna studie är att undersöka förskollärare och barnskötares arbete för en inkluderande verksamhet med barn i behov av särskilt stöd. Genom samtalsintervjuer som metod har vi fått en fördjupad kunskap kring inkludering och barn i behov av särskilt stöd. Med utgångspunkt i Haugs (1998) teori kring integrering, har vi i två separata delstudier analyserat förskollärares och barnskötares uppfattning kring begreppet inkludering, miljöns betydelse för en inkluderande verksamhet samt hur förskollärare och barnskötare uppfattar sin egen kompetens i relation till arbetet med barn i behov av särskilt stöd. Studiens resultat visar att förskollärarna i studien besitter en bredare kompetens kring inkludering med barn i behov av särskilt stöd än vad barnskötarna väljer att beskriva i studien. Dock är de båda yrkesgrupperna överens om att inkludering i förskolan är viktigt och att miljön har stor betydelse för ett inkluderande arbetssätt. De båda yrkesgrupperna är överens om att inkludering innebär att alla barn kan vara med. Barnen ska ges möjligheten att delta samt att varje barns behov och förutsättningar ska tillgodoses.
Full text
DiVA
2020
Scandinavian Journal of Immunology
article-journal
Screening for autoantibody targets in post-vaccination narcolepsy using proteome arrays
Alexander Lind, Daniel Eriksson, Omar Akel, Anita Ramelius, Lars Palm, Ake Lernmark, Olle Kämpe, Helena Elding Larsson, Nils Landegren
Abstract
Narcolepsy type 1 (NT1) is a chronic sleep disorder caused by a specific loss of hypocretin‐producing neurons. The incidence of NT1 increased in Sweden, Finland and Norway following Pandemrix®‐vaccination, initiated to prevent the 2009 influenza pandemic. The pathogenesis of NT1 is poorly understood, and causal links to vaccination are yet to be clarified. The strong association with Human leukocyte antigen (HLA) DQB1*06:02 suggests an autoimmune pathogenesis, but proposed autoantigens remain controversial. We used a two‐step approach to identify autoantigens in patients that acquired NT1 after Pandemrix®‐vaccination. Using arrays of more than 9000 full‐length human proteins, we screened the sera of 10 patients and 24 healthy subjects for autoantibodies. Identified candidate antigens were expressed in vitro to enable validation studies with radiobinding assays (RBA). The validation cohort included NT1 patients (n = 39), their first‐degree relatives (FDR) (n = 66), population controls (n = 188), and disease controls representing multiple sclerosis (n = 100) and FDR to type 1 diabetes patients (n = 41). Reactivity towards previously suggested NT1 autoantigen candidates including Tribbles homolog 2, Prostaglandin D2 receptor, Hypocretin receptor 2 and α‐MSH/proopiomelanocortin was not replicated in the protein array screen. By comparing case to control signals, three novel candidate autoantigens were identified in the protein array screen; LOC401464, PARP3 and FAM63B. However, the RBA did not confirm elevated reactivity towards either of these proteins. In summary, three putative autoantigens in NT1 were identified by protein array screening. Autoantibodies against these candidates could not be verified with independent methods. Further studies are warranted to identify hypothetical autoantigens related to the pathogenesis of Pandemrix®‐induced NT1.
DOI
DiVA
2020
Cell
article-journal
The Immunology of Multisystem Inflammatory Syndrome in Children with COVID-19
Camila Rosat Consiglio, Nicola Cotugno, Fabian Sardh, Christian Pou, Donato Amodio, Lucie Rodriguez, Ziyang Tan, Sonia Zicari, Alessandra Ruggiero, Giuseppe Rubens Pascucci, Veronica Santilli, Tessa Campbell, Yenan Bryceson, Daniel Eriksson, Jun Wang, Alessandra Marchesi, Tadepally Lakshmikanth, Andrea Campana, Alberto Villani, Paolo Rossi, Nils Landegren, Paolo Palma, Petter Brodin
Abstract
Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection is typically very mild and often asymptomatic in children. A complication is the rare multisystem inflammatory syndrome in children (MIS-C) associated with COVID-19, presenting 4-6 weeks after infection as high fever, organ dysfunction, and strongly elevated markers of inflammation. The pathogenesis is unclear but has overlapping features with Kawasaki disease suggestive of vasculitis and a likely autoimmune etiology. Weapply systems-level analyses of blood immune cells, cytokines, and autoantibodies in healthy children, children with Kawasaki disease enrolled prior to COVID-19, children infected with SARS-CoV-2, and children presenting with MIS-C. We find that the inflammatory response in MIS-C differs from the cytokine storm of severe acute COVID-19, shares several features with Kawasaki disease, but also differs from this condition with respect to T cell subsets, interleukin (IL)-17A, and biomarkers associated with arterial damage. Finally, autoantibody profiling suggests multiple autoantibodies that could be involved in the pathogenesis of MIS-C.
DOI
DiVA
2019
eLIFE
article-journal
Comment on 'AIRE-deficient patients harbor unique high-affinity disease-ameliorating autoantibodies'
Nils Landegren, Lindsey B. Rosen, Eva Freyhult, Daniel Eriksson, Tove Fall, Gustav Smith, Elise M. N. Ferre, Petter Brodin, Donald Sharon, Michael Snyder, Michail Lionakis, Mark Anderson, Olle Kampe
Abstract
The AIRE gene plays a key role in the development of central immune tolerance by promoting thymic presentation of tissue-specific molecules. Patients with AIRE-deficiency develop multiple autoimmune manifestations and display autoantibodies against the affected tissues. In 2016 it was reported that: i) the spectrum of autoantibodies in patients with AIRE-deficiency is much broader than previously appreciated; ii) neutralizing autoantibodies to type I interferons (IFNs) could provide protection against type 1 diabetes in these patients (Meyer et al., 2016). We attempted to replicate these new findings using a similar experimental approach in an independent patient cohort, and found no evidence for either conclusion.
DOI
DiVA
2019
Journal of Allergy and Clinical Immunology
article-journal
The autoimmune targets in IPEX are dominated by gut epithelial proteins
Daniel Eriksson, Rosa Bacchetta, Hörður Ingi Gunnarsson, Alice Chan, Federica Barzaghi, Stephan Ehl, Åsa Hallgren, Frederic van Gool, Fabian Sardh, Christina Lundqvist, Saila M. Laakso, Anders Rönnblom, Olov Ekwall, Outi Mäkitie, Sophie Bensing, Eystein S. Husebye, Mark Anderson, Olle Kämpe, Nils Landegren
DOI
DiVA
2018
Scientific Reports
article-journal
Common genetic variation in the autoimmune regulator (AIRE) locus is associated with autoimmune Addison's disease in Sweden
Daniel Eriksson, Matteo Bianchi, Nils Landegren, Frida Dalin, Jakob Skov, Lina Hultin-Rosenberg, Argyri Mathioudaki, Jessika Nordin, Asa Hallgren, Goran Andersson, Karolina Tandre, Solbritt Rantapaa Dahlqvist, Peter Soderkvist, Lars Rönnblom, Anna-Lena Hulting, Jeanette Wahlberg, Per Dahlqvist, Olov Ekwall, Jennifer Meadows, Kerstin Lindblad-Toh, Sophie Bensing, Gerli Pielberg, Olle Kampe
Abstract
Autoimmune Addison's disease (AAD) is the predominating cause of primary adrenal failure. Despite its high heritability, the rarity of disease has long made candidate-gene studies the only feasible methodology for genetic studies. Here we conducted a comprehensive reinvestigation of suggested AAD risk loci and more than 1800 candidate genes with associated regulatory elements in 479 patients with AAD and 2394 controls. Our analysis enabled us to replicate many risk variants, but several other previously suggested risk variants failed confirmation. By exploring the full set of 1800 candidate genes, we further identified common variation in the autoimmune regulator (AIRE) as a novel risk locus associated to sporadic AAD in our study. Our findings not only confirm that multiple loci are associated with disease risk, but also show to what extent the multiple risk loci jointly associate to AAD. In total, risk loci discovered to date only explain about 7% of variance in liability to AAD in our study population.
DOI
DiVA
2018
Journal of Clinical Endocrinology and Metabolism
article-journal
Cytokine Autoantibody Screening in the Swedish Addison Registry Identifies Patients With Undiagnosed APS1
Daniel Eriksson, Frida Dalin, Gabriel Nordling Eriksson, Nils Landegren, Matteo Bianchi, Åsa Hallgren, Per Dahlqvist, Jeanette Wahlberg, Olov Ekwall, Ola Winqvist, Sergiu-Bogdan Catrina, Johan Rönnelid, Anna-Lena Hulting, Kerstin Lindblad-Toh, Mohammad Alimohammad, Eystein S Husebye, Per Morten Knappskog, Gerli Rosengren Pielberg, Sophie Bensing, Olle Kämpe
Abstract
Context: Autoimmune polyendocrine syndrome type 1 (APS1) is a monogenic disorder that features autoimmune Addison disease as a major component. Although APS1 accounts for only a small fraction of all patients with Addison disease, early identification of these individuals is vital to prevent the potentially lethal complications of APS1.Objective: To determine whether available serological and genetic markers are valuable screening tools for the identification of APS1 among patients diagnosed with Addison disease.Design: We systematically screened 677 patients with Addison disease enrolled in the Swedish Addison Registry for autoantibodies against interleukin-22 and interferon-α4. Autoantibody-positive patients were investigated for clinical manifestations of APS1, additional APS1-specific autoantibodies, and DNA sequence and copy number variations of AIRE.Results: In total, 17 patients (2.5%) displayed autoantibodies against interleukin-22 and/or interferon-α4, of which nine were known APS1 cases. Four patients previously undiagnosed with APS1 fulfilled clinical, genetic, and serological criteria. Hence, we identified four patients with undiagnosed APS1 with this screening procedure.Conclusion: We propose that patients with Addison disease should be routinely screened for cytokine autoantibodies. Clinical or serological support for APS1 should warrant DNA sequencing and copy number analysis of AIRE to enable early diagnosis and prevention of lethal complications.
DOI
DiVA
2018
Brain and Behavior
article-journal
Early fine motor impairment and behavioral dysfunction in (Thy-1)-h[A30P] alpha-synuclein mice
Sara Ekmark-Lewén, Veronica Lindstrom, Astrid Gumucio, Elisabet Ihse, Anish Behere, Philipp J. Kahle, Eva Nordstrom, Maria Eriksson, Anna Erlandsson, Joakim Bergström, Martin Ingelsson
Abstract
Introduction: Intraneuronal inclusions of alpha-synuclein are commonly found in the brain of patients with Parkinson's disease and other a-synucleinopathies. The correlation between alpha-synuclein pathology and symptoms has been studied in various animal models. In (Thy-1)-h[A30P] alpha-synuclein transgenic mice, behavioral and motor abnormalities were reported from 12 and 15 months, respectively. The aim of this study was to investigate whether these mice also display symptoms at earlier time points.Methods: We analyzed gait deficits, locomotion, and behavioral profiles in (Thy-1)-h[A30P] alpha-synuclein and control mice at 2, 8, and 11 months of age. In addition, inflammatory markers, levels of alpha-synuclein oligomers, and tyrosine hydroxylase reactivity were studied.Results: Already at 2 months of age, transgenic mice displayed fine motor impairments in the challenging beam test that progressively increased up to 11 months of age. At 8 months, transgenic mice showed a decreased general activity with increased risk-taking behavior in the multivariate concentric square field test. Neuropathological analyses of 8- and 11-month-old mice revealed accumulation of oligomeric alpha-synuclein in neuronal cell bodies. In addition, a decreased presence of tyrosine hydroxylase suggests a dysregulation of the dopaminergic system in the transgenic mice, which in turn may explain some of the motor impairments observed in this mouse model.Conclusions: Taken together, our results show that the (Thy-1)-h[A30P] alpha-synuclein transgenic mouse model displays early Parkinson's disease-related symptoms with a concomitant downregulation of the dopaminergic system. Thus, this should be an -appropriate model to study early phenotypes of alpha-synucleinopathies.
DOI
DiVA
2018
Scientific Reports
article-journal
ILF2 and ILF3 are autoantigens in canine systemic autoimmune disease
Hanna D. Bremer, Nils Landegren, Ronald Sjöberg, Åsa Hallgren, Stefanie Renneker, Erik Lattwein, Dag Leonard, Maija-Leena Eloranta, Lars Rönnblom, Gunnel Nordmark, Peter Nilsson, Goran Andersson, Inger Lilliehöök, Kerstin Lindblad-Toh, Olle Kämpe, Helene Hansson-Hamlin
Abstract
Dogs can spontaneously develop complex systemic autoimmune disorders, with similarities to human autoimmune disease. Autoantibodies directed at self-antigens are a key feature of these autoimmune diseases. Here we report the identification of interleukin enhancer-binding factors 2 and 3 (ILF2 and ILF3) as autoantigens in canine immune-mediated rheumatic disease. The ILF2 autoantibodies were discovered in a small, selected canine cohort through the use of human protein arrays; a method not previously described in dogs. Subsequently, ILF3 autoantibodies were also identified in the same cohort. The results were validated with an independent method in a larger cohort of dogs. ILF2 and ILF3 autoantibodies were found exclusively, and at a high frequency, in dogs that showed a speckled pattern of antinuclear antibodies on immunofluorescence. ILF2 and ILF3 autoantibodies were also found at low frequency in human patients with SLE and Sjogren's syndrome. These autoantibodies have the potential to be used as diagnostic biomarkers for canine, and possibly also human, autoimmune disease.
DOI
DiVA
2016
Journal of Clinical Endocrinology and Metabolism
article-journal
A Longitudinal Follow-up of Autoimmune Polyendocrine Syndrome Type 1
Oyvind Bruserud, Bergithe E. Oftedal, Nils Landegren, Martina M. Erichsen, Eirik Bratland, Kari Lima, Anders P. Jorgensen, Anne G. Myhre, Johan Svartberg, Kristian J. Fougner, Asne Bakke, Bjorn G. Nedrebo, Bjarne Mella, Lars Breivik, Marte K. Viken, Per M. Knappskog, Mihaela C. Marthinussen, Kristian Lovas, Olle Kampe, Anette B. Wolff, Eystein S. Husebye
Abstract
Context:Autoimmune polyendocrine syndrome type 1 (APS1) is a childhood-onset monogenic disease defined by the presence of two of the three major components: hypoparathyroidism, primary adrenocortical insufficiency, and chronic mucocutaneous candidiasis (CMC). Information on longitudinal follow-up of APS1 is sparse.Objective: To describe the phenotypes of APS1 and correlate the clinical features with autoantibody profiles and autoimmune regulator (AIRE) mutations during extended follow-up (1996-2016).Patients: All known Norwegian patients with APS1.Results: Fifty-two patients from 34 families were identified. The majority presented with one of the major disease components during childhood. Enamel hypoplasia, hypoparathyroidism, and CMC were the most frequent components. With age, most patients presented three to five disease manifestations, although some had milder phenotypes diagnosed in adulthood. Fifteen of the patients died during follow-up (median age at death, 34 years) or were deceasedsiblingswithahighprobability of undisclosed APS1. All except three had interferon-omega) autoantibodies, and allhadorgan-specific autoantibodies. The most common AIRE mutation was c.967_979del13, found in homozygosity in 15 patients. A mild phenotype was associated with the splice mutation c.879+1G>A. Primary adrenocortical insufficiency and type 1 diabetes were associated with protective human leucocyte antigen genotypes.Conclusions: Multiple presumable autoimmune manifestations, in particular hypoparathyroidism, CMC, and enamel hypoplasia, should prompt further diagnostic workup using autoantibody analyses (eg, interferon-omega) and AIRE sequencing to reveal APS1, even in adults. Treatment is complicated, and mortality is high. Structured follow-up should be performed in a specialized center.
DOI
DiVA
2016
Ophthalmology
book
Aryl Hydrocarbon Receptor-Interacting Protein-Like 1 in Cancer-Associated Retinopathy
Frida Dalin, Grazyna Adamus, Sufang Yang, Eva Landgren, Josefine Palle, Åsa Hallgren, B M Frost, Therese Hugosson, Nils Landegren, Daniel Eriksson, Sten Andreasson, Khalid F. Tabbara, Olle Kämpe, Mohammad Alimohammadi
DOI
DiVA
2016
Journal of the American Society of Nephrology
article-journal
Autoantibodies Targeting a Collecting Duct-Specific Water Channel in Tubulointerstitial Nephritis.
Nils Landegren, Mina Pourmousa Lindberg, Jakob Skov, Åsa Hallgren, Daniel Eriksson, Trine Lisberg Toft-Bertelsen, Nanna MacAulay, Eva Hagforsen, Anne Räisänen-Sokolowski, Heikki Saha, Thomas Nilsson, Gunnel Nordmark, Sophie Ohlsson, Jan Gustafsson, Eystein S Husebye, Erik Larsson, Mark S Anderson, Jaakko Perheentupa, Fredrik Rorsman, Robert A Fenton, Olle Kämpe
Abstract
Tubulointerstitial nephritis is a common cause of kidney failure and may have diverse etiologies. This form of nephritis is sometimes associated with autoimmune disease, but the role of autoimmune mechanisms in disease development is not well understood. Here, we present the cases of three patients with autoimmune polyendocrine syndrome type 1 who developed tubulointerstitial nephritis and ESRD in association with autoantibodies against kidney collecting duct cells. One of the patients developed autoantibodies targeting the collecting duct-specific water channel aquaporin 2, whereas autoantibodies of the two other patients reacted against the HOXB7 or NFAT5 transcription factors, which regulate the aquaporin 2 promoter. Our findings suggest that tubulointerstitial nephritis developed in these patients as a result of an autoimmune insult on the kidney collecting duct cells.
DOI
DiVA
2016
Journal of Internal Medicine
article-journal
Extended exome sequencing identifies BACH2 as a novel major risk locus for Addison's disease
D. Eriksson, Matteo Bianchi, Nils Landegren, Jessika Nordin, Frida Dalin, Argyri Mathioudaki, G. N. Eriksson, Lina Hultin-Rosenberg, Johanna Dahlqvist, H. Zetterqvist, Andreas Karlsson, Anna Hallgren, F. H. G. Farias, Eva Murén, Kerstin M. Ahlgren, Anna Lobell, G. Andersson, Karolina Tandre, S. R. Dahlqvist, P. Soderkvist, Lars Rönnblom, A. -L Hulting, J. Wahlberg, O. Ekwall, P. Dahlqvist, Jennifer R. S. Meadows, S. Bensing, Kerstin Lindblad-Toh, Olle Kämpe, Gerli R. Pielberg
Abstract
BackgroundAutoimmune disease is one of the leading causes of morbidity and mortality worldwide. In Addison's disease, the adrenal glands are targeted by destructive autoimmunity. Despite being the most common cause of primary adrenal failure, little is known about its aetiology. MethodsTo understand the genetic background of Addison's disease, we utilized the extensively characterized patients of the Swedish Addison Registry. We developed an extended exome capture array comprising a selected set of 1853 genes and their potential regulatory elements, for the purpose of sequencing 479 patients with Addison's disease and 1394 controls. ResultsWe identified BACH2 (rs62408233-A, OR = 2.01 (1.71-2.37), P = 1.66 x 10(-15), MAF 0.46/0.29 in cases/controls) as a novel gene associated with Addison's disease development. We also confirmed the previously known associations with the HLA complex. ConclusionWhilst BACH2 has been previously reported to associate with organ-specific autoimmune diseases co-inherited with Addison's disease, we have identified BACH2 as a major risk locus in Addison's disease, independent of concomitant autoimmune diseases. Our results may enable future research towards preventive disease treatment.
DOI
DiVA
2016
Scientific Reports
article-journal
Proteome-wide survey of the autoimmune target repertoire in autoimmune polyendocrine syndrome type 1
Nils Landegren, Donald Sharon, Eva Freyhult, Åsa Hallgren, Daniel Eriksson, Per-Henrik Edqvist, Sophie Bensing, Jeanette Wahlberg, Lawrence M Nelson, Jan Gustafsson, Eystein S Husebye, Mark S Anderson, Michael Snyder, Olle Kämpe
Abstract
Autoimmune polyendocrine syndrome type 1 (APS1) is a monogenic disorder that features multiple autoimmune disease manifestations. It is caused by mutations in the Autoimmune regulator (AIRE) gene, which promote thymic display of thousands of peripheral tissue antigens in a process critical for establishing central immune tolerance. We here used proteome arrays to perform a comprehensive study of autoimmune targets in APS1. Interrogation of established autoantigens revealed highly reliable detection of autoantibodies, and by exploring the full panel of more than 9000 proteins we further identified MAGEB2 and PDILT as novel major autoantigens in APS1. Our proteome-wide assessment revealed a marked enrichment for tissue-specific immune targets, mirroring AIRE's selectiveness for this category of genes. Our findings also suggest that only a very limited portion of the proteome becomes targeted by the immune system in APS1, which contrasts the broad defect of thymic presentation associated with AIRE-deficiency and raises novel questions what other factors are needed for break of tolerance.
DOI
DiVA